Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy.
Jenny J Ko, Brandon Bernard, Ben Tran, Haocheng Li, Tehmina Asif, Igor Stukalin, Margaret Lee, Daphne Day, Nimira Alimohamed, Christopher J Sweeney, Philippe L Bedard, Daniel YC Heng
Journal of Clinical Oncology | Published : 2016
PURPOSE: The International Germ Cell Cancer Collaborative Group (IGCCCG) criteria prognosticate survival outcomes in metastatic testicular germ cell tumor (MT-GCT), but how the initial risk changes over time for those who survived since curative treatment is unknown. PATIENTS AND METHODS: We assessed patients eligible for first-line therapy for MT-GCT at five tertiary cancer centers from 1990 to 2012 for 2-year conditional overall survival (COS) and conditional disease-free survival (CDFS), defined as the probability of surviving, or surviving and being disease free, respectively, for an additional 2 years at a given time point since the initial diagnosis. RESULTS: For all patients (N = 942)..View full abstract